+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of drug treatment of myocardial infarction in public hospitals of Andalusia. GAUME (Andalusian Group for performance of Studies on Drug Utilization)



Evaluation of drug treatment of myocardial infarction in public hospitals of Andalusia. GAUME (Andalusian Group for performance of Studies on Drug Utilization)



Medicina Clinica 111(9): 329-335



The management of patients with acute myocardial infarction (AMI) has changed over the last decade. The aim of this study was to evaluate the pharmacologic treatment of AMI in the clinical practice, with special emphasis in thrombolytic therapy. Prospective drug utilization survey, collecting data from 26 hospitals belonging to the Andalusian Health Service, Spain, during one month period. Pharmacologic treatment in the first 24 h was obtained. Out of 379 patients recruited, 52.8% received thrombolytic therapy, although another 19% could have obtained some benefit from that therapy. Alteplase was the most frequently used thrombolytic (65.5%). The regimen prescribed was mainly that followed in GUSTO Study (45.8%) or double bolus (43.5%). In a high percentage of patients the thrombolytic selection was not made according to the results of the literature. Women and patients older than 75 years were less likely to receive thrombolytic therapy. There was a high utilization of aspirin (89.7%), nitrates (84.4%) and heparin (83.6%). Thrombolytic therapy was prescribed in a higher percentage of patients than is reported in other trials. In spite of that, thrombolytics should have been used in more patients. As alteplase does not have a definitive benefit over streptokinase, protocol is needed when selecting a thrombolytic agent.

(PDF emailed within 1 workday: $29.90)

Accession: 046009372

Download citation: RISBibTeXText

PMID: 9810534


Related references

Acute myocardial infarction treatments in 58 Italian hospitals: a drug utilization survey. Annals of PharmacoTherapy 29(11): 1100-1105, 1995

Thrombolytic treatment for myocardial infarction: an examination of practice in 39 United Kingdom hospitals. Myocardial Infarction Audit Group. Heart 78(1): 28-33, 1997

Evaluation of rational drug use based on World Health Organization core drug use indicators in selected public hospitals of eastern Ethiopia: a cross sectional study. Bmc Health Services Research 17(1): 161, 2017

Drug-Eluting Versus Bare Metal Stents in Patients With ST-SegmentElevation Myocardial Infarction. Eight-Month Follow-Up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) Trial. Yearbook of Cardiology 2009: 261-262, 2009

Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 118(11): 1155-1162, 2008

Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction). Jacc. Cardiovascular Interventions 6(6): 548-553, 2014

Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. Journal of the American College of Cardiology 56(8): 641-645, 2010

The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia 43(2): 218-226, 2001

Drug utilization in patients before and after acute myocardial infarction. Journal of Clinical Research & Pharmacoepidemiology 4(2): 132-133, 1990

Natural history of myocardial infarction in the coronary drug project: long-term prognostic importance of serum lipid levels. Coronary Drug Project Research Group. American Journal of Cardiology 42(3): 489-498, 1978

Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara regional state public hospitals; Ethiopia: a retrospective cohort study. Bmc Infectious Diseases 19(1): 286, 2019

Treatable risk factors--hypercholesterolemia, smoking, and hypertension--after myocardial infarction: implications of the coronary drug project data for clinical management. Coronary Drug Project Research Group. Primary Care 7(1): 175-179, 1980

Utilization of Recently Established Drug Information Centers Located in the Public Hospitals of Addis Ababa, Ethiopia: An Assessment. Therapeutic Innovation and Regulatory Science 48(3): 378-385, 2014

Drug-eluting vs. bare-metal stents for treatment of acute myocardial infarction with renal insufficiency. Results from Korea Acute Myocardial Infarction Registry. Circulation Journal 75(12): 2798-2804, 2012

Utilization of in vitro drug-drug interaction studies in drug discovery/development. Pharmaceutical Research (New York) 13(9 SUPPL ): S558, 1996